• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RREB1 抑制 miR-143/145 通过下调多个靶标调节 KRAS 信号。

RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.

机构信息

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

出版信息

Oncogene. 2013 May 16;32(20):2576-85. doi: 10.1038/onc.2012.266. Epub 2012 Jul 2.

DOI:10.1038/onc.2012.266
PMID:22751122
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8177721/
Abstract

A lack of expression of miR-143 and miR-145 has been demonstrated to be a frequent feature of colorectal tumors. Activating KRAS mutations have been reported in 30-60% of colorectal cancers and an inverse correlation between Kras and miR-143/145 expression has been observed. Previously, we have demonstrated that oncogenic Kras leads to repression of the miR-143/145 cluster in pancreatic cancer and is dependent on the Ras responsive element (RRE) binding protein (RREB1), which negatively regulates miR-143/145 expression. In the present study, we have found that RREB1 is overexpressed in colorectal adenocarcinoma tumors and cell lines, and the expression of the miR-143/145 primary transcript is inversely related to RREB1 expression. In colorectal cancer cell lines, the miR-143/145 cluster is repressed by RREB1 downstream of constitutively active KRAS. RREB1 is activated by the MAPK pathway and negatively represses the miR-143/145 promoter through interaction with two RREs. In addition, overexpression of miR-143 or miR-145 in HCT116 cells abrogates signaling through the MAPK, PI3K and JNK pathways by downregulation of both KRAS and RREB1 in addition to downregulation of a cohort of genes in the MAPK signaling cascade. These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer.

摘要

miR-143 和 miR-145 的表达缺失已被证实是结直肠肿瘤的一个常见特征。据报道,在 30%-60%的结直肠癌中存在 KRAS 激活突变,并且已经观察到 Kras 与 miR-143/145 表达之间存在反相关。先前,我们已经证明致癌性 Kras 导致胰腺癌中 miR-143/145 簇的抑制,并且依赖于 Ras 反应元件 (RRE) 结合蛋白 (RREB1),其负调节 miR-143/145 的表达。在本研究中,我们发现 RREB1 在结直肠腺癌肿瘤和细胞系中过表达,并且 miR-143/145 初级转录物的表达与 RREB1 表达呈负相关。在结直肠癌细胞系中,RREB1 通过组成性激活的 KRAS 下游抑制 miR-143/145 簇的表达。RREB1 被 MAPK 途径激活,并通过与两个 RRE 相互作用负向抑制 miR-143/145 启动子。此外,在 HCT116 细胞中过表达 miR-143 或 miR-145 通过下调 KRAS 和 RREB1 以及下调 MAPK 信号级联中的一组基因,阻断 MAPK、PI3K 和 JNK 途径的信号传导。这些结果建立了一个复杂的调控网络,通过该网络,miR-143/145 簇能够调节结直肠癌中的 KRAS 信号。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/5be3e529171c/nihms-1706886-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/2eb49c2b189f/nihms-1706886-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/f3cdd971a3ff/nihms-1706886-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/b5f382c6af48/nihms-1706886-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/6c98e2d7f947/nihms-1706886-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/5be3e529171c/nihms-1706886-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/2eb49c2b189f/nihms-1706886-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/f3cdd971a3ff/nihms-1706886-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/b5f382c6af48/nihms-1706886-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/6c98e2d7f947/nihms-1706886-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e53c/8177721/5be3e529171c/nihms-1706886-f0005.jpg

相似文献

1
RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.RREB1 抑制 miR-143/145 通过下调多个靶标调节 KRAS 信号。
Oncogene. 2013 May 16;32(20):2576-85. doi: 10.1038/onc.2012.266. Epub 2012 Jul 2.
2
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.致癌性 Ras 对 miR-143/145 簇的抑制作用启动了促肿瘤发生的正反馈通路。
Genes Dev. 2010 Dec 15;24(24):2754-9. doi: 10.1101/gad.1950610.
3
Crocin Suppresses Colorectal Cancer Cell Proliferation by Regulating miR-143/145 and KRAS/RREB1 Pathways.藏红花酸通过调节 miR-143/145 和 KRAS/RREB1 通路抑制结直肠癌细胞增殖。
Anticancer Agents Med Chem. 2023;23(17):1916-1923. doi: 10.2174/1871520623666230718145100.
4
RAS-Responsive Element-Binding Protein 1 Blocks the Granulocytic Differentiation of Myeloid Leukemia Cells.RAS 反应元件结合蛋白 1 阻止髓系白血病细胞的粒细胞分化。
Oncol Res. 2019 Jul 12;27(7):809-818. doi: 10.3727/096504018X15451301487729. Epub 2019 Apr 8.
5
Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.致癌性 KRAS 以三维特异性方式调节结直肠癌细胞中的 miR-200c 和 miR-221/222。
Anticancer Res. 2011 Jul;31(7):2453-9.
6
Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.致癌性KRAS对miR-31的转录调控通过抑制RASA1介导转移表型。
Mol Cancer Res. 2016 Mar;14(3):267-77. doi: 10.1158/1541-7786.MCR-15-0456. Epub 2016 Jan 8.
7
ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.ARID1A 通过依赖于 AP1 的方式促进结直肠癌细胞中 KRAS 信号调节的增强子活性。
Clin Epigenetics. 2019 Jun 19;11(1):92. doi: 10.1186/s13148-019-0690-5.
8
Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes.RREB1单倍体不足通过RAS-MAPK途径基因的表观遗传重编程导致类努南综合征的RAS病。
Nat Commun. 2020 Sep 16;11(1):4673. doi: 10.1038/s41467-020-18483-9.
9
miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.致癌性KRAS诱导产生的miR-450b-5p是结直肠癌进展所必需的。
Oncotarget. 2016 Sep 20;7(38):61312-61324. doi: 10.18632/oncotarget.11016.
10
EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.EVI1 癌基因通过抑制 microRNA-96 促进胰腺发生中的 KRAS 通路。
Oncogene. 2014 May 8;33(19):2454-63. doi: 10.1038/onc.2013.204. Epub 2013 Jun 10.

引用本文的文献

1
The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications.微小RNA在结直肠癌中的多方面作用:发病机制及治疗意义
Noncoding RNA Res. 2025 May 23;14:65-95. doi: 10.1016/j.ncrna.2025.05.012. eCollection 2025 Oct.
2
Identification of a Distal Enhancer That Regulates TGF-β-Induced SNAI1 Expression.鉴定调控转化生长因子-β诱导的SNAI1表达的远端增强子
Cancer Sci. 2025 May 13. doi: 10.1111/cas.70091.
3
Plasma miR-145-5p Levels and Risk of Future Cancer-Results from the HUNT Study.血浆miR-145-5p水平与未来患癌风险——HUNT研究结果

本文引用的文献

1
MicroRNA profiling differentiates colorectal cancer according to KRAS status.MicroRNA 谱可根据 KRAS 状态区分结直肠癌。
Genes Chromosomes Cancer. 2012 Jan;51(1):1-9. doi: 10.1002/gcc.20925. Epub 2011 Sep 15.
2
miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation.miR-143 过表达通过诱导细胞凋亡和抑制增殖来损害小鼠人结肠癌异种移植物的生长。
PLoS One. 2011;6(8):e23787. doi: 10.1371/journal.pone.0023787. Epub 2011 Aug 25.
3
RREB1 transcription factor splice variants in urologic cancer.
Int J Mol Sci. 2025 Feb 28;26(5):2191. doi: 10.3390/ijms26052191.
4
Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.丝裂原活化蛋白激酶(MAPK)信号与鸟嘌呤核苷酸交换因子GEF-H1的动态偶联
Onco Targets Ther. 2025 Jan 25;18:147-159. doi: 10.2147/OTT.S496228. eCollection 2025.
5
RREB1-mediated SUMOylation enhancement promotes chemoresistance partially by transcriptionally upregulating in colorectal cancer.RREB1介导的SUMO化增强通过转录上调部分促进结直肠癌的化疗耐药性。
Front Pharmacol. 2024 Jul 23;15:1381860. doi: 10.3389/fphar.2024.1381860. eCollection 2024.
6
Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain.在动物中模拟甲基苯丙胺使用障碍和复发:大鼠脑中长期和短期的表观遗传、转录和生化后果。
Neurosci Biobehav Rev. 2023 Dec;155:105440. doi: 10.1016/j.neubiorev.2023.105440. Epub 2023 Oct 29.
7
Non-coding RNAs in exercise immunology: A systematic review.非编码 RNA 在运动免疫学中的作用:系统评价。
J Sport Health Sci. 2024 May;13(3):311-338. doi: 10.1016/j.jshs.2023.11.001. Epub 2023 Nov 3.
8
Novel insights on perils and promises of miRNA in understanding colon cancer metastasis and progression.微小 RNA 在理解结肠癌转移和进展中的危险与希望的新见解。
Med Oncol. 2023 Aug 28;40(10):282. doi: 10.1007/s12032-023-02099-2.
9
miR-125b-5p, miR-155-3p, and miR-214-5p and Target Gene in Oral Squamous Cell Carcinoma.miR-125b-5p、miR-155-3p 和 miR-214-5p 及其在口腔鳞状细胞癌中的靶基因。
Int J Mol Sci. 2023 Mar 28;24(7):6320. doi: 10.3390/ijms24076320.
10
MicroRNAs in cancer metastasis: biological and therapeutic implications.微小 RNA 与癌症转移:生物学与治疗意义。
Expert Rev Mol Med. 2023 Mar 17;25:e14. doi: 10.1017/erm.2023.7.
泌尿生殖系统癌症中的 RREB1 转录因子剪接变体。
Am J Pathol. 2011 Jul;179(1):477-86. doi: 10.1016/j.ajpath.2011.03.038.
4
EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.EGFR 信号下调西方饮食促进的小鼠结肠癌中的肿瘤抑制因子 miR-143 和 miR-145:G1 调节因子的作用。
Mol Cancer Res. 2011 Jul;9(7):960-75. doi: 10.1158/1541-7786.MCR-10-0531. Epub 2011 Jun 8.
5
Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation.c-Jun NH(2)-末端激酶在 Ras 引发的肿瘤形成中的作用。
Mol Cell Biol. 2011 Apr;31(7):1565-76. doi: 10.1128/MCB.01122-10. Epub 2011 Jan 31.
6
ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth.ShRNA 靶向 MAP4K4 抑制肝癌生长。
Clin Cancer Res. 2011 Feb 15;17(4):710-20. doi: 10.1158/1078-0432.CCR-10-0331. Epub 2010 Dec 30.
7
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.致癌性 Ras 对 miR-143/145 簇的抑制作用启动了促肿瘤发生的正反馈通路。
Genes Dev. 2010 Dec 15;24(24):2754-9. doi: 10.1101/gad.1950610.
8
Lowered HGK expression inhibits cell invasion and adhesion in hepatocellular carcinoma cell line HepG2.低表达 HGK 抑制肝癌细胞系 HepG2 中的细胞侵袭和黏附。
World J Gastroenterol. 2010 Sep 28;16(36):4541-8. doi: 10.3748/wjg.v16.i36.4541.
9
Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.MicroRNA-21 对 K-Ras 依赖性肺肿瘤发生的调节作用。
Cancer Cell. 2010 Sep 14;18(3):282-93. doi: 10.1016/j.ccr.2010.08.013.
10
A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer.五基因标志物可作为结直肠癌转移和生存的潜在预测指标。
J Pathol. 2010 Mar;220(4):475-89. doi: 10.1002/path.2668.